Trastuzumab Recruiting Phase 2 Trials for Neoplasms / Tumors, Solid / Bladder Cancers / Biliary Cancer / Salivary Cancer Treatment

Indications	Status	Purpose	Phase
DBCOND0027948 (Neoplasms) DBCOND0074335 (Tumors, Solid) DBCOND0050427 (Bladder Cancers) DBCOND0038607 (Biliary Cancer) DBCOND0080787 (Salivary Cancer)	Recruiting	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT02091141	My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors	Vemurafenib (DB08881) Erlotinib (DB00530) Pertuzumab (DB06366) Trastuzumab (DB00072) Cobimetinib (DB05239) Vismodegib (DB08828) Alectinib (DB11363) Atezolizumab (DB11595)